Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells

Oncology Research

Volumn 22, Issue 4, 2015, Pages 193-201

  Wang, Yunshan ^a,b   Wei, Junmin ^c   Li, Li ^a   Fan, Cong ^c   Sun, Ying ^c  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Adenosine 5 monophosphate activated protein kinase (AMPK); Breast cancer; Everolimus; Mammalian target of rapamycin (mTOR); Metformin

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; METFORMIN; PROTEIN S6; ANTINEOPLASTIC AGENT; EIF4EBP1 PROTEIN, HUMAN; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME ACTIVATORS; EVEROLIMUS; FEMALE; METFORMIN; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941660744     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504015X14348950540999     Document Type: Article

References (23)

1. Hubbard, P. A.; Moody, C. L.; Murali, R. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging therapeutic opportunities. Front. Physiol. 5:478; 2014.
2. Hosford, S. R.; Miller, T. W. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics Pers. Med. 7:203-215; 2014.
3. Paplomata, E.; O'Regan, R. The PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and biomarkers. Ther. Adv. Med. Oncol. 6:154-166; 2014.
4. Gonzalez-Angulo, A. M.; Blumenschein, Jr., G. R. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat. Rev. 39:313-320; 2013.
5. Foretz, M.; Guigas, B.; Bertrand, L.; Pollak, M.; Viollet, B. Metformin: From mechanisms of action to therapies. Cell Metab. 20:953-966; 2014.
6. Kasznicki, J.; Sliwinska, A.; Drzewoski, J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2:57; 2014.
7. Aldea, M.; Craciun, L.; Tomuleasa, C.; Berindan-Neagoe, I.; Kacso, G.; Florian, I. S.; Crivii, C. Repositioning metformin in cancer: Genetics, drug targets, and new ways of delivery. Tumour Biol. 35:5101-5110; 2014.
8. Hajjar, J.; Habra, M. A.; Naing, A. Metformin: An old drug with new potential. Expert Opin. Investig. Drugs. 22:1511-1517; 2013.
9. Rizos, C. V.; Elisaf, M. S. Metformin and cancer. Eur. J. Pharmacol. 705:96-108; 2013.
10. Boyle, J. G.; Salt, I. P.; McKay, G. A. Metformin action on AMP-activated protein kinase: A translational research approach to understanding a potential new therapeutic target. Diabetic Med. 27:1097-1106; 2010.
11. Amato, R.; Stepankiw, M. Evaluation of everolimus in renal cell cancer. Expert Opin. Pharmacother. 14:1229-1240; 2013.
12. Yao, J. C.; Shah, M. H.; Ito, T.; Bohas, C. L.; Wolin, E. M.; Van Cutsem, E.; Hobday, T. J.; Okusaka, T.; Capdevila, J.; de Vries, E. G.; Tomassetti, P.; Pavel, M. E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Oberg, K. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364:514-523; 2011.
13. Eyre, T. A.; Collins, G. P.; Goldstone, ; Cwynarski, K. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. Br. J. Haematol. 166:336-351; 2014.
14. Huang, Y.; Xi, Q.; Chen, Y.; Wang, J.; Peng, P.; Xia, S.; Yu, S. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Anticancer Drugs 24:889-898; 2013.
15. Lau, Y. K.; Du, X.; Rayannavar, V.; Hopkins, B.; Shaw, J.; Bessler, E.; Thomas, T.; Pires, M. M.; Keniry, M.; Parsons, R. E.; Cremers, S.; Szabolcs, M.; Maurer, M. A. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget 5:10503-10517; 2014.
16. Goodwin, P. J.; Stambolic, V. Obesity and insulin resistance in breast cancer - Chemoprevention strategies with a focus on metformin. Breast 20(Suppl 3):S31-5; 2011.
17. Leone, A.; Di Gennaro, E.; Bruzzese, F.; Avallone, A.; Budillon, A. New perspective for an old antidiabetic drug: Metformin as anticancer agent. Cancer Treat. Res. 159:355-376; 2014.
18. Ma, J.; Guo, Y.; Chen, S.; Zhong, C.; Xue, Y.; Zhang, Y.; Lai, X.; Wei, Y.; Yu, S.; Zhang, J.; Liu, W. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer 14:172; 2014.
19. Liu, B.; Fan, Z.; Edgerton, S. M.; Deng, X. S.; Alimova, I. N.; Lind, S. E.; Thor, A. D. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031-2040; 2009.
20. Zhang, X.; Li, X. R.; Zhang, J. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer. Curr. Cancer Drug Targets 13:175-187; 2013.
21. Dawood, S.; Austin, L.; Cristofanilli, M. Cancer stem cells: Implications for cancer therapy. Oncology 28(12):1101-1107, 1110; 2014.
22. Nakshatri, H.; Srour, E. F.; Badve, S. Breast cancer stem cells and intrinsic subtypes: Controversies rage on. Curr. Stem Cell Res. Ther. 4:50-60; 2009.
23. deBeca, F. F.; Caetano, P.; Gerhard, R.; Alvarenga, C. A.; Gomes, M.; Paredes, J.; Schmitt, F. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J. Clin. Pathol. 66:187-191; 2013.